The current financial score of LENZ Therapeutics Inc is 6.26. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 3.38M, representing a year-over-year decrease of 72.93%, while its net profit experienced a year-over-year decrease of 85.44%.
The current valuation score of LENZ Therapeutics Inc is 7.98. Its current P/E ratio is -0.96, which is -5145.97% below the recent high of 48.49 and -3038.23% above the recent low of -30.16.
The current earnings forecast score of LENZ Therapeutics Inc is 8.29. The average price target is 15.00, with a high of 45.00 and a low of 4.00.
The current price momentum score of LENZ Therapeutics Inc is 5.02. Currently, the stock price is trading between the resistance level at 3.89 and the support level at 2.96, making it suitable for range-bound swing trading.
The current institutional shareholding score of LENZ Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 115.82%, representing a quarter-over-quarter increase of 6.75%.
The current risk assessment score of LENZ Therapeutics Inc is 3.20. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.